LUM001 (Maralixibat)

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Alagille Syndrome

Conditions

Alagille Syndrome

Trial Timeline

Dec 20, 2013 → Jun 17, 2020

NCT ID

NCT02047318

About LUM001 (Maralixibat)

LUM001 (Maralixibat) is a phase 2 stage product being developed by Mirum Pharmaceuticals for Alagille Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02047318. Target conditions include Alagille Syndrome.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02117713	Phase 2	Completed	Mar 16, 2015	Jun 1, 2020	Alagille Syndrome
NCT02057718	Phase 2	Completed	Mar 1, 2014	May 8, 2020	Progressive Familial Intrahepatic Cholestasis (PFIC)
NCT02047318	Phase 2	Completed	Dec 20, 2013	Jun 17, 2020	Alagille Syndrome

Competing Products

9 competing products in Alagille Syndrome

See all competitors

Product	Company	Stage	Hype Score
Odevixibat + Placebo	Ipsen	Phase 3	74
Odevixibat	Ipsen	Phase 3	74
LUM001 (Maralixibat)	Mirum Pharmaceuticals	Phase 2	49
maralixibat	Mirum Pharmaceuticals	Pre-clinical	20
Livmarli + Livmarli	Mirum Pharmaceuticals	Pre-clinical	20
LUM001 (Maralixibat) + Placebo	Mirum Pharmaceuticals	Phase 2	49
Livmarli Oral Product	Mirum Pharmaceuticals	Approved	82
LUM001 + Placebo	Mirum Pharmaceuticals	Phase 2	49
LUM001 + Placebo	Mirum Pharmaceuticals	Phase 2	49

Other Products from Mirum Pharmaceuticals

Livmarli Oral ProductApproved